Could a common diabetes drug heal scarred hearts?
NCT ID NCT07294495
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether henagliflozin, a drug currently used for diabetes, can reduce scarring in the heart muscle of people with a type of hypertrophic cardiomyopathy (non-obstructive HCM). The trial will enroll 150 adults and use special PET scans to measure changes in scar tissue over 6 months. If successful, it may offer a new treatment option for this heart condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Henagliflozin (a diabetes drug that may also reduce heart scarring)
- What this could lead to
- If it works, this could point toward a new way to reduce heart scarring and improve outcomes in hypertrophic cardiomyopathy.
- What could go wrong
- This is an early-phase trial with only 150 people, so results may not apply broadly. The drug is being tested for a new purpose and may not show benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCM - HYPERTROPHIC CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, 200120, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.